Hims & Hers Health, Inc.(HIMS)
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
Latest News & Analysis
Hims & Hers Stock Surge: Growth Drivers and Market Outlook
Latest analysis reveals Hims & Hers's robust growth, strategic marketing, and expansion fueling its stock surge amid a competitive telehealth market.
Hims & Hers Health, Inc.: Adapting to Market Shifts and Diversifying Growth
Hims & Hers faces market shifts due to GLP-1 drug availability. Strategic acquisitions and diversification are key to navigating the evolving landscape.
Hims & Hers (HIMS): Weight-Loss Strategy, Competition, and Risks
Hims & Hers Health, Inc. navigates telehealth competition, expands weight-loss offerings, and faces regulatory risks. A comprehensive analysis of HIMS's strategic moves and market dynamics.
Hims & Hers Health, Inc. Market Update: Strategic Positioning and Financial Insights
Hims & Hers Health, Inc. shows strategic momentum with solid stock performance and evolving market positioning as of June 2025.
Hims & Hers Health, Inc. (HIMS) Latest Financial and Strategic Update
Explore Hims & Hers Health's recent financial performance, strategic moves, and market positioning with data-driven insights for investors.
Hims & Hers Health, Inc. (HIMS) Latest Legal Challenges and Financial Performance Analysis
Explore Hims & Hers Health, Inc.'s recent securities fraud lawsuit, partnership termination, and financial growth insights impacting investor decisions.
Hims & Hers Health, Inc. Legal Challenges and Financial Performance Analysis
Hims & Hers faces securities fraud allegations and partnership termination with Novo Nordisk, impacting its stock and financial fundamentals.
Hims & Hers Health, Inc. Latest Corporate Developments and Financial Analysis
In-depth analysis of Hims & Hers Health's recent legal challenges, partnership termination, and financial performance revealing strategic and market impacts.
Hims & Hers Health (HIMS) Faces Legal Turbulence Amid Novo Nordisk Fallout and Strategic Shifts
Hims & Hers Health stock surges +4.66% post legal setbacks tied to Novo Nordisk partnership dispute, revealing key financial impacts and strategic pivots in 2025.
Hims & Hers Health Inc. (HIMS) Faces Legal Turbulence Amid Novo Nordisk Split and Market Volatility
Hims & Hers Health (HIMS) confronts securities fraud allegations after Novo Nordisk partnership ends, causing sharp stock drop and investor scrutiny.
Hims & Hers Health, Inc. (HIMS) Lawsuit Impact and Financial Analysis - Monexa AI
Hims & Hers Health faces securities fraud lawsuit with significant stock volatility and financial shifts; detailed analysis of recent developments and future outlook.
Hims & Hers Health, Inc. (HIMS) Legal Challenges and Financial Resilience: A Data-Driven Analysis
Explore how Hims & Hers Health, Inc. (HIMS) navigates securities fraud allegations amid strong revenue growth and improving profitability.
Hims & Hers Health, Inc. (HIMS) Faces Securities Fraud Lawsuit Amid Market Volatility
Hims & Hers Health, Inc. (HIMS) confronts securities fraud allegations linked to deceptive marketing, triggering sharp stock declines and investor lawsuits.
Hims & Hers Health Inc. Latest Legal Challenges and Financial Analysis - Monexa AI
Explore Hims & Hers Health's recent legal challenges, partnership termination, and robust financial growth with detailed market and financial analysis.
Hims & Hers Health (HIMS) Legal Turmoil and Partnership Fallout Impact Financials and Strategy
Hims & Hers Health faces securities fraud lawsuits and a key partnership termination with Novo Nordisk, impacting its financials and strategic outlook.
Hims & Hers Health Inc. (HIMS) Faces Legal Turmoil Amid Strong Financial Growth
Hims & Hers Health, Inc. confronts securities fraud allegations amid strong revenue growth, stock volatility, and evolving telehealth sector dynamics.
Hims & Hers Health, Inc. (HIMS) Lawsuit Impact & Financial Analysis August 2025
Detailed analysis of Hims & Hers Health, Inc.'s recent securities fraud lawsuit, financial performance, and strategic implications for investors as of August 2025.
Hims & Hers (HIMS): GLP-1 Revenue Shock & Lawsuit
Hims & Hers faces a sharp re-pricing after GLP‑1 revenue weakness, a Novo Nordisk partnership termination and a pending securities class action — here’s the data-driven impact.
Hims & Hers: Q2 Revenue Shock, GLP‑1 Drop & CEO $33M Sale
Hims & Hers reports a sharp GLP‑1 revenue pullback, Q2 miss and CEO $33.4M sale; analysis of financials, cash flow, regulatory risk and the Aug 25 lead‑plaintiff deadline.
Hims & Hers (HIMS): Profitability Turnaround Collides With Legal and Regulatory Overhang
Hims & Hers reported **FY2024 revenue of $1.48B** and **net income of $126.04M**, yet shares trade under pressure after a >34% intraday plunge and an active FTC probe into advertising and cancellation practices.
Hims & Hers (HIMS): Strong 2024 Financials, But Novo Nordisk Breakup and Class Actions Raise Material Risk
Hims & Hers posted **$1.48B revenue** and **$126.0M net income** in FY2024, but Novo Nordisk's termination and related securities suits triggered a ~-31%–35% one‑day drop and a fresh legal/regulatory storm.
Hims & Hers (HIMS): Profit Turnaround, Cash Strength and a Legal Overhang
Hims & Hers reported **FY2024 revenue of $1.48B** and **net income of $126.0M**, but a partnership termination and securities suits create a material near‑term risk.
Hims & Hers (HIMS): Litigation Storm vs. Real Cashflow Momentum
Novo Nordisk’s June termination sent HIMS down ~30% and spawned class actions — yet FY‑2024 shows **$1.48B** revenue and **$198M** free cash flow with **$300M** cash on hand, creating a high‑volatility story.